Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Values First Advisors Inc.

Values First Advisors Inc. grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 9.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 35,921 shares of the company’s stock after acquiring an additional 3,239 shares during the quarter. Values First Advisors Inc.’s holdings in Elanco Animal Health were worth $535,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Comerica Bank acquired a new position in Elanco Animal Health during the 3rd quarter worth $40,000. Advisory Services Network LLC lifted its holdings in shares of Elanco Animal Health by 104.1% in the first quarter. Advisory Services Network LLC now owns 5,204 shares of the company’s stock valued at $49,000 after buying an additional 2,654 shares during the period. Captrust Financial Advisors lifted its holdings in shares of Elanco Animal Health by 57.0% in the first quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock valued at $70,000 after buying an additional 977 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at $70,000. Finally, Covestor Ltd lifted its holdings in shares of Elanco Animal Health by 1,285.1% in the first quarter. Covestor Ltd now owns 2,978 shares of the company’s stock valued at $78,000 after buying an additional 2,763 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 0.7 %

NYSE:ELAN traded up $0.11 during trading hours on Thursday, hitting $16.28. 2,321,901 shares of the company’s stock traded hands, compared to its average volume of 4,410,575. The firm has a market cap of $8.03 billion, a P/E ratio of -6.47, a P/E/G ratio of 1.67 and a beta of 1.29. Elanco Animal Health Incorporated has a twelve month low of $7.88 and a twelve month high of $16.88. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.35 and a current ratio of 2.75. The stock’s fifty day moving average price is $15.75 and its two-hundred day moving average price is $13.27.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.02). Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the company earned $0.19 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director R David Hoover acquired 20,000 shares of Elanco Animal Health stock in a transaction on Wednesday, March 6th. The stock was bought at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the transaction, the director now owns 185,000 shares of the company’s stock, valued at $2,985,900. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Jefferies Financial Group assumed coverage on Elanco Animal Health in a report on Tuesday, December 19th. They issued a “buy” rating and a $17.00 price objective for the company. Morgan Stanley upped their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Stifel Nicolaus raised Elanco Animal Health from a “hold” rating to a “buy” rating and upped their target price for the company from $13.00 to $20.00 in a report on Friday, January 5th. TheStreet raised Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Finally, Barclays upped their target price on Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.71.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.